Corrigendum: Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real‐world setting.

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. In Table 3, the confidence interval for the age group >=50 <70 for immune checkpoint inhibitors (ICIs) was 0.17-1.18, rather than 0.17-1.78, and the third category for Performance status (PS) was 3-4 but was automatically converted to 03-Apr. Finally, in the univariable analyses of BMI for ICIs in Table 4, the p-value for BMI as a continuous variable should be 0.736, while that for BMI >=30 was in fact 0.298 rather than 0.2980.736, as the two values ended up in the same cell. Corrigendum: Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. [Extracted from the article]